Gestational diabetes & diabetes in pregnancy
Maternal fasting serum C-peptide concentrations in the first and second trimesters and subsequent risk of gestational diabetes mellitus: A nested case-control study among Chinese women
Authors' conclusion
Our findings revealed a positive correlation between fasting serum C-peptide during the first and second trimesters and the risk of GDM or its subtypes, underscoring the potential of C-peptide as a predictor for GDM development.
Study context
- Population
- Reproductive-aged Chinese women, Beijing, China, January 2016–December 2017
- Participants
- 436 women
- Comparison
- Gestational diabetes mellitus (GDM) cases vs controls: fasting serum C-peptide in first and second trimesters
- GDM casesn = 218
- Controlsn = 218reference
- Outcome
- GDM risk by fasting serum C-peptide
- Follow-up
- 10-14 and 15-20 weeks of gestation
Methodological detailsmatched 1:1 by maternal age
- Matched 1:1 by maternal age
Main finding
As reported in the abstract
GDM risk per 1 log ng/mL increase of fasting serum C-peptide
First trimester: OR
2.38
95% CI 1.33–4.40
Second trimester: OR
3.07
95% CI 1.49–6.62
Observational data: associations, not effects.
Further findings
Predictive capacity of C-peptide for GDM (AUC)
- AUC, first-trimester C-peptide
- 80.4%
- AUC, second-trimester C-peptide
- 82.4%
Fasting serum C-peptide change in women with normal glucose tolerance (NGT) · first to second trimester
- Significant decrease from the initial to the subsequent trimester in women with NGT
Original publication
Maternal fasting serum C-peptide concentrations in the first and second trimesters and subsequent risk of gestational diabetes mellitus: A nested case-control study among Chinese women. Diabetes Res Clin Pract. Published 23 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →